Cellectis (CLLS) to Release Quarterly Earnings on Monday

Key Points

• Q1 2026 results due Monday, May 11: Cellectis is expected to report results after the close on May 11 (call noted at 2:00 AM ET) with analysts forecasting EPS of ($0.2583) and revenue of $11.04M.
• In the prior quarter the company missed EPS (reported ($0.26) vs. consensus ($0.10)) but beat revenue expectations ($15.50M vs. $10.74M), while showing large negative profitability metrics (negative ROE and net margin).
• Shares recently traded up (to $3.94) with a market cap around $395M; Wall Street sentiment is mixed but averages a "Moderate Buy" rating and a mean price target of $6.75, and institutional investors own about 63.9% of the stock.

Cellectis (NASDAQ:CLLS - Get Free Report) will likely be announcing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.2583) per share and revenue of $11.0390 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 2:00 AM ET.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its earnings results on Thursday, March 19th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.16). The company had revenue of $15.50 million for the quarter, compared to analysts' expectations of $10.74 million. Cellectis had a negative return on equity of 69.38% and a negative net margin of 84.92%.

Cellectis Trading Up 4.7%

Shares of NASDAQ:CLLS traded up $0.18 during trading on Wednesday, reaching $3.94. 2,461 shares of the company were exchanged, compared to its average volume of 41,924. The firm has a market capitalization of $394.84 million, a PE ratio of -5.87 and a beta of 2.94. The business's fifty day simple moving average is $3.69 and its 200-day simple moving average is $4.01. Cellectis has a 12-month low of $1.33 and a 12-month high of $5.48. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.62 and a quick ratio of 1.62.

Wall Street Analyst Weigh In

CLLS has been the topic of a number of research reports. Jefferies Financial Group initiated coverage on shares of Cellectis in a research report on Tuesday, February 17th. They set a "buy" rating and a $7.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cellectis in a research report on Monday, April 20th. Finally, Citizens Jmp reaffirmed a "market outperform" rating and set a $8.00 target price on shares of Cellectis in a research report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Cellectis currently has an average rating of "Moderate Buy" and an average price target of $6.75.

Hedge Funds Weigh In On Cellectis

Institutional investors have recently bought and sold shares of the business. Marshall Wace LLP boosted its stake in Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company's stock valued at $864,000 after acquiring an additional 168,038 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Cellectis in the fourth quarter valued at approximately $15,385,000. Global Retirement Partners LLC acquired a new stake in Cellectis in the fourth quarter valued at approximately $34,000. Millennium Management LLC boosted its stake in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company's stock valued at $165,000 after acquiring an additional 22,080 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Cellectis in the third quarter valued at approximately $633,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company's core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.